Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells

A protein and binding site technology, applied in the direction of hybrid immunoglobulin, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, anti-animal/human immunoglobulin, etc., can solve adverse side effects, etc. question

Pending Publication Date: 2020-12-04
DRAGONFLY THERAPEUTICS INC
View PDF16 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Current treatment options for these cancers are not effective in all patients and / or may have serious adverse side effects
Treating other types of cancer with existing treatment options also remains challenging

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
  • Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
  • Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-N

[0265] Example 1 - NKG2D binding domain binds to NKG2D

[0266] NKG2D binding domain binds to purified recombinant NKG2D

[0267] The nucleic acid sequence of human, mouse or cynomolgus NKG2D ectodomain is fused with the nucleic acid sequence encoding human IgG1 Fc domain, and introduced into mammalian cells for expression. After purification, the NKG2D-Fc fusion protein was adsorbed to the wells of a microwell plate. After blocking the wells with bovine serum albumin to prevent non-specific binding, the NKG2D-binding domain was titrated and added to the wells pre-adsorbed with NKG2D-Fc fusion protein. Primary antibody binding was detected using a secondary antibody conjugated to horseradish peroxidase and specifically recognizing human kappa light chain to avoid Fc cross-reactivity. 3,3',5,5'-Tetramethylbenzidine (TMB), a substrate for horseradish peroxidase, was added to the wells to observe the binding signal, its absorbance was measured at 450 nM and corrected at 540 n...

Embodiment 2

[0272] Example 2 - NKG2D Binding Domains Block the Binding of Natural Ligands to NKG2D

[0273] Compete with ULBP-6

[0274] The recombinant human NKG2D-Fc protein was adsorbed to the wells of the microwell plate, and the wells were blocked with bovine serum albumin to reduce non-specific binding. A saturating concentration of ULBP-6-His-biotin was added to the wells, followed by NKG2D-binding domain clones. After 2 hours of incubation, the wells were washed and ULBP-6-His-biotin still bound to NKG2D-Fc-coated wells was detected by horseradish peroxidase-conjugated streptavidin and TMB substrate. Absorbance was measured at 450 nM and corrected at 540 nM. After background subtraction, the specific binding of the NKG2D binding domain to the NKG2D-Fc protein was calculated from the percentage of ULBP-6-His-biotin that was blocked from binding to the NKG2D-Fc protein in the wells. Positive control antibodies (selected from SEQ ID NO:45-48) and various NKG2D binding domains bl...

Embodiment 3-N

[0279] Example 3 - NKG2D binding domain cloning activates NKG2D

[0280] The nucleic acid sequences of human and mouse NKG2D were fused to the nucleic acid sequence encoding the CD3ζ signaling domain to obtain chimeric antigen receptor (CAR) constructs. Then, the NKG2D-CAR construct was cloned into a retroviral vector using Gibson assembly and transfected into expi293 cells to generate retrovirus. EL4 cells were infected with virus containing NKG2D-CAR and 8 μg / mL polybrene. 24 hours after infection, the expression level of NKG2D-CAR in EL4 cells was analyzed by flow cytometry, and clones expressing high levels of NKG2D-CAR on the cell surface were selected.

[0281] To determine whether NKG2D-binding domains activate NKG2D, they were adsorbed to wells of microplates, and NKG2D-CAR EL4 cells were incubated with antibody fragment-coated wells in the presence of brefeldin A and monensin. Incubate for 4 hours. Intracellular TNF-[alpha] production (an indicator of NKG2D activat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A combination therapy of a cancer with a multi-specific binding protein that bind a tumor associated antigen, the NKG2D receptor, and CD16, in combination with a second anti-cancer agent are described. Also described are pharmaceutical compositions of the multi-specific binding protein, and therapeutic methods useful for the treatment of cancer in combination with a second anti-cancer agent.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 628,178, filed February 8, 2018, the disclosure of which is incorporated by reference in its entirety for all purposes. technical field [0003] Cancer combination therapy using a multispecific binding protein that binds a tumor-associated antigen, NKG2D receptor and CD16 in combination with a second anti-cancer agent is described. Also described are pharmaceutical compositions of the multispecific binding proteins, as well as therapeutic methods for treating cancer in combination with a second anticancer agent. Background technique [0004] Despite numerous research efforts and scientific advances reported in the literature for the treatment of cancer, the disease remains an important health problem. Some of the most commonly diagnosed cancers include prostate, breast, and lung. Prostate cancer is the most common form o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61K39/395C07K16/28C07K16/30C07K16/46C12N5/0783
CPCC07K2319/03C07K14/7051A61K39/0011C07K16/2851C07K16/32C07K16/2803C07K16/2887C07K16/2878A61P35/00C07K2317/31A61K2039/505A61K2039/507C07K16/2818A61K39/39558A61K39/3955A61K38/2013A61K38/208A61K38/2086A61K31/337A61K45/06A61K31/675A61K39/464417A61K39/464411A61K39/4631A61K39/464429A61K39/4613A61K2239/57A61K39/464406A61K39/464424A61K2300/00A61K39/395A61K38/17C07K16/28C07K16/30C07K16/46A61K47/6929A61K47/643A61P35/02A61K31/7084C07K14/55C07K16/283C07K2317/52C07K2317/524C07K2317/53C07K2317/565C07K2317/569C07K2317/732C07K2317/734C07K2317/94
Inventor 格雷戈里·P·常安·F·张阿斯亚·格林贝格伊娃·古铁雷斯威廉·哈尼尼科莱·瓦戈曼布拉德利·M·伦德比昂卡·普林茨
Owner DRAGONFLY THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com